Me-too diabetes drugs look good enough for Lilly

June 26, 2013
Back to TopCommentsE-mailPrintBookmark and Share

Who says the age of me-too drugs is over?

Eli Lilly and Co. is more than 15 years late to the game in the world of diabetes drugs. And it isn’t bringing much that doctors and patients haven’t already seen.

Still, with diabetes getting out of control across the globe, it looks like Lilly has arrived in time to make a few billion a year.

The Indianapolis-based drugmaker was the global pioneer in diabetes medicines when it introduced the first animal-based insulin in 1923 and the first biotech insulin in 1982.

But as I have described before, Lilly missed the boat in the late 1990s and early 2000s on non-insulin medicines for Type 2 diabetics—particularly oral medications that don’t require injections, something patients desperately try to avoid.

Lilly’s sales of diabetes medicines have been growing only about half as fast as its competitors ever since.

But Lilly appears to be staging a comeback. It rolled out a raft of data about its diabetes drugs this past weekend. The numbers look good.

Problem is, they don’t look any better than drugs that are already on the market. Lilly’s experimental drug dulaglutide will compete with Novo Nordisk A/S’ Victoza and Bristol-Myers Squibb Co.’s Bydureon. Lilly’s empagliflozin will compete with Johnson & Johnson’s Invokana, which recently won approval from U.S. regulators.

“There does not appear to be much clinical differentiation in terms of efficacy and side effects,” wrote Morgan Stanley David Risinger, in a June 24 note to investors. Marc Goodman, a pharmaceutical analyst at UBS, said the same.

Still, Lilly will likely find customers, for a couple of reasons. First, dulaglutide is a once-weekly medicine, compared with Victoza’s daily dose. Results of a head-to-head trial of the two drugs are due early next year.

Also, the new drugs will allow Lilly to offer a whole range of medicines to diabetics, not just its insulins. And that portfolio approach will help it pick up sales, since patients and doctors often like to stick with one manufacturer throughout the course of their disease.

“In our view, Lilly will benefit from having a broader portfolio of diabetes drugs that covers the entire treatment paradigm,” Risinger wrote.

By 2020, Lilly could pull in roughly $1 billion each from dulaglutide, empagliflozin and a new long-acting insulin, according to Risinger. He gives the drugs 85 percent or 90 percent chances of being approved.

Other analysts have roughly similar estimates.

Extra sales of $3 billion a year are just what the doctors at Lilly ordered. That’s because the company is in the process of losing nearly $10 billion in annual sales because of patent expirations between 2010 and 2014 on four of its blockbuster drugs.

Of course, $3 billion does not equal $10 billion. So Wall Street analysts want to see something else, such as Lilly’s experimental cancer drug ramucirumab. Lilly is trying to differentiate that drug from Avastin, which has become a $3-billion-a-year powerhouse as a treatment against numerous kinds of cancer.

Some are optimistic, but as I wrote earlier this month, recent failures made others jittery.

“With the upcoming expirations of Cymbalta and Evista, we are less than optimistic on Lilly’s late stage pipeline being able to account for the sales cliff post-2014,” Goodman wrote to investors on June 25.

But Lilly has shown a remarkable ability to wring sales out of me-too drugs. Consider its current best-seller Cymbalta. When approved in 2004, it was the umpteenth antidepressant on the market. Yet the drug has actually accelerated its sales late in its life, rising from $3 billion in 2009 to $5 billion last year.

The Lilly brass are banking more than a little that they can keep it up for a few more years until, they hope, their pipeline produces a game-changer.

What do you all think? Can me-too drugs be enough to help Lilly muddle through its challenges that lie ahead?

  • Facts vs PR
    Data released this week by EvaluatePharma shows that in 2012, Lilly's sales of biotech products (of which insulin is part) ranked 9th in the world at $5.3 billion. This was well below the leader, Roche, with $26.7 billion. Can Lilly explain how it fell so far behind in a market that it created? If one listens to Lilly's corporate pronouncements over the last 15 years, they are replete with glorification of what was in effect under-performance. Lilly still has one of the most respected R&D organization in the industry. But the fact that so many talented people have not really brought much to the market since 2004 raises disturbing questions about the company's failure to harness its creative assets. Unless this situation is addressed head-on, and radical changes are made, there is every reason to fear that Lilly's disastrous biotech performance will repeat itself -- and will be labeled a great achievement. The company clearly faces a leadership issue that the board must address. Worldwide Prescription Drug Sales from Biotechnology in 2012: 1. Roche $26.7 bn 2. Amgen: $15.5 3. Sanofi: $13.4 4. Novo: $12.6 5. Pfizer: $10.3 6. Abbvie: $10.1 7. J&J: $8.1 8: Merck: 7.4 9. Lilly: 5.3 10. GSK: 4.8
  • prof of curmudgeony
    The problem with science, medicine and the stock market is that accurately predicting the future is impossible. We keep trying because it is fun. Lilly has strong management, good science and is investing heavily in taking chances. They are the historic leader in diabetes and it makes sense to broaden that franchise. We can't know which drugs will be better for which patients until we get a lot of data. Anticipate surprises, but don't fear them. Fear causes disease.

Post a comment to this blog

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
  1. Liberals do not understand that marriage is not about a law or a right ... it is a rite of religous faith. Liberals want "legal" recognition of their homosexual relationship ... which is OK by me ... but it will never be classified as a marriage because marriage is a relationship between a man and a woman. You can gain / obtain legal recognition / status ... but most people will not acknowledge that 2 people of the same sex are married. It's not really possible as long as marriage is defined as one man and one woman.

  2. That second phrase, "...nor make or enforce any law which shall abridge the privileges or immunitites of citizens..." is the one. If you can't understand that you lack a fundamental understanding of the Constitution and I can't help you. You're blind with prejudice.

  3. Why do you conservatives always go to the marrying father/daughter, man/animal thing? And why should I keep my sexuality to myself? I see straights kissy facing in public all the time.

  4. I just read the XIV Amendment ... I read where no State shall deprive any person of life, liberty, or property ... nor make or enforce any law which shall abridge the privileges or immunitites of citizens ... I didn't see anything in it regarding the re-definition of marriage.

  5. I worked for Community Health Network and the reason that senior leadership left is because they were not in agreement with the way the hospital was being ran, how employees were being treated, and most of all how the focus on patient care was nothing more than a poster to stand behind. Hiring these analyst to come out and tell people who have done the job for years that it is all being done wrong now...hint, hint, get rid of employees by calling it "restructuring" is a cheap and easy way out of taking ownership. Indiana is an "at-will" state, so there doesn't have to be a "reason" for dismissal of employment. I have seen former employees that went through this process lose their homes, cars, is very disturbing. The patient's as well have seen less than disireable care. It all comes full circle.